Facebook
Twitter
LinkedIn
Forward
Targeting DED: Aiming Treatments at Optimal Results (In-Person CE Symposium)
To register for the symposium, please click Register/Take Course.
Wednesday, November 6, 2024
6:00 PM – 6:30 PM ET Registration and Dinner
6:30 PM – 8:30 PM ET CE Symposium and Virtual Broadcast
Indianapolis Artsgarden
110 West Washington Street
Indianapolis, Indiana
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Incorporate diagnostic strategies for DED into practice
- Review the pathophysiologic factors of DED
- Design evidence-based treatment plans for patients with DED
Faculty
 | Kelly K. Nichols, OD, MPH, PhD, FAAO (Chair) |
 | Selina McGee, OD, FAAO |
 | Justin A. Schweitzer, OD, FAAO |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Selina McGee, OD, FAAO, is a consultant for AbbVie Inc, Aldeyra Therapeutics, Amgen Inc, Avellino, Bruder Healthcare, Cynosure, Dompé US, Inc, Eyevance, Harrow, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Optovue, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries Ltd, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, Topcon Medical Systems, Inc, Trukera, and Versant Ventures; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Cynosure, Dompé US, Inc, Lumenis, Optovue, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.
Kelly K. Nichols, OD, MPH, PhD, FAAO, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics*, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, Cavalry Biosciences, Dompé US, Inc, HanAll Biopharma*, Harrow, Inc, Nicox*, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Osmotica Pharmaceuticals plc*, Oyster Point Pharma, Inc, Palatin Technologies, Inc*, RVL Pharmaceuticals, Inc*, Sight Sciences, Takeda Pharmaceuticals USA, Inc, Tarsus Pharmaceuticals, Inc, TearSolutions, Thea Pharma Inc, Topcon Medical Systems, Inc, TopiVert Ltd*, Trukera, Verséa Health, Inc, and Xequel Bio*; is on the speakers bureau for Bausch & Lomb Incorporated*; is a contracted researcher for Aramis Biosciences, KOWA Pharmaceuticals America, Inc, ScienceBased Health, Sylentis, and TearScience; and is a stockholder or has stock options in Axim Biotechnologies Inc* and Oyster Point Pharma, Inc*.
Justin A. Schweitzer, OD, FAAO, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Astellas Pharma Inc, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Kala Pharmaceuticals, LKC Technologies, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Quidel Corporation, Reichert, Inc, RVL Pharmaceuticals, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Bausch & Lomb Incorporated, Glaukos Corporation, LKC Technologies, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss; and is on the advisory board of AbbVie Inc, Aerie Pharmaceuticals, Inc, Alcon, Astellas Pharma Inc, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Visus Therapeutics, and Zeiss.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 91799-TD (Synchronous In Person)
COPE Course Category: Treatment and Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 129110, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 319.7
Available Credit
- 2.00 COPE
To register for this symposium, please select the purple Take course button. You will receive an email confirmation. If you do not receive a confirmation, please check your spam folder or email info@mededicus.com.
We look forward to seeing you in Indianapolis on November 6!